Results 111 to 120 of about 827 (146)

Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer. [PDF]

open access: yesJ Comp Eff Res
Graybill WS   +23 more
europepmc   +1 more source

3D bioprinted breast tumor-stroma models for pre-clinical drug testing. [PDF]

open access: yesMater Today Bio, 2023
González-Callejo P   +6 more
europepmc   +1 more source

Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients. [PDF]

open access: yesClin Cancer Res, 2023
Pascual J   +22 more
europepmc   +1 more source

Physician-reported patient involvement and treatment decisions in first-line ovarian cancer in the USA and Europe. [PDF]

open access: yesInt J Gynecol Cancer
Moore KN   +9 more
europepmc   +1 more source

Biomarkers in Ovarian Pathology: From Screening to Diagnosis. Review of the Literature. [PDF]

open access: yesJ Pers Med, 2021
Elorriaga MÁ   +4 more
europepmc   +1 more source

[Health professionals' perspective about women's experiences during the diagnostic process of ovarian cancer in Catalonia: Qualitative study]. [PDF]

open access: yesAten Primaria, 2023
Marzo-Castillejo M   +5 more
europepmc   +1 more source

El uso de anticonceptivos orales reduciría el riesgo de cáncer ginecológico

open access: yesEvidencia. Actualización en la Práctica Ambulatoria, 2008
Juliana Alicia Botbol
doaj   +1 more source

Home - About - Disclaimer - Privacy